25/02/20 -"For FY20, revenue is expected to be lower than in FY19 as the majority of the sales milestone related to Darzalex was realised in FY19. Also, as R&D spend will continue to remain high – to accelerate ..."
Pages
49
Language
English
Published on
25/02/20
You may also be interested by these reports :
17/04/24
Q1 sales exceeded expectations, driven by a strong performance from the Companion Animal segment. The Farm Animal segment was however held back by a ...
16/04/24
Preview: Positive 1Q24 driven by clinical developments of portfolio companies
15/04/24
Investor appetite for Merck KGaA (Add, Germany) shares has been somewhat subdued since we last teased the name (15/03/2021). At that time, the ...
15/04/24
Turnaround story on track – TP increased to CHF 30.00 (from CHF 25.00) – Add reiterated